Let’s go for 3! Easier on patients and maybe easier on surgery. Also perhaps a faster path to identify nonresponders or those who progress and guide them to other therapy. #ELCC24

✅ Redoing Tony Mok Q after update on FLAURA-2: How much chemotherapy is needed added on top of #osimertinib to obtain the benefit of the combination? Would short course induction therapy w/o maintenance pemetrexed be enough? ⬇️ Adherence on trial to pemetrexed #ELCC24 ESMO - Eur. Oncology

Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC - Journal of Thoracic Oncology jto.org/article/S1556-…

Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC - Journal of Thoracic Oncology jto.org/article/S1556-…

Exploratory #ctDNA analysis of the FLAURA2 trial by Pasi Jänne Dana-Farber #AACR24 👉 Comparable EGFR mutation clearance in ctDNA at 6 weeks, in both arms. EGFR Resisters #LCSM

FLAURA2- Baseline detection of ctDNA may identify a subgroup of pts who derive most benefit from addition of chemoT to osimertinib as first line trtt for EGFRmut NSCLC by P.Jänne at #AACR24 EGFR Resisters Dana Farber's EGFR-Mutant Lung Cancer Center Gustave Roussy Dana-Farber News

Outstanding talk covering locally advanced and oligometastatic lung cancer from incoming School of Medicine Trinity St James's Cancer Institute Marie Curie Prof. Gerry Hanna #ailcc24 #lcsm

Abstract Submission is now open for #ACLC24, taking place Oct. 17-19 in Hong Kong. Showcase your research & share in discussions w/experts in the field, shaping the future of treatments in #lungcancer & thoracic malignancies. Learn More & Submit here:bit.ly/ACLC24-AbSub #LCSM

#IASLC 2024 Asia Conference on Lung Cancer #ACLC24 will be held in 🇭🇰Hong Kong, China, from October 17-19, 2024. Don't hesitate to submit your abstracts!

A circulating tumor DNA-guided adaptive de-escalation TKI treatment strategy is feasible for patients with advanced NSCLC and undetectable ctDNA for achieving complete remission after local consolidative therapy. ja.ma/4cjYJMC

Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC) - Journal of Thoracic Oncology jto.org/article/S1556-…

Our paper just out on Cancer Cell: IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable and more patients without recurrence than that received CCRT. Thanks all investigators from 15 sites in China. It is impossible without their hard works!

Thank you Prof. Fred R. Hirsch for the insightful speech! 🎤

A promising conceptual study. We still need a more detailed definition of 'borderline resectable.'

#LCSM 🫁CA colleagues, IASLC Career Development Committee will have a pre-conference workshop on IASLC grant💰application at #WCLC24. We have a list of fantastic faculty for this interactive workshop. If you're going to #WCLC24, pre sign-up for a spot! cattendee.abstractsonline.com/meeting/20598/…

Journey to San Diego ☀ #WCLC24 #IASLC50 #IASLC

Excited to attend #WCLC24 and celebrate the 50th anniversary of IASLC! Looking forward to the inspiring discussions and connecting with global experts. Let’s make this milestone event unforgettable! 🎉 #IASLC50 #LungCancer

#WCLC24 Happening now! IASLC Career Development Committee's IASLC grant workshop at RM22. Small group discussion is ongoing. If you missed it, come at 🕜1:45PM for 1. IASLC Grant Program Review 2. IASLC Grant Recipient's experience 3. What's an exceptional grant proposal